The Msi2 Protein Expression Positive Correlation with Favorable Cytogenetics Findings in AML
Msi2 Protein Expression in AML and Cytogenetics
Vol. 12 No. 1 : 2017 (66-82)
Abstract
Acute myeloid leukaemia (AML) is the most common subtype of acute leukaemias with a poor outcome. Msi2 protein is a newly discovered prognostic marker and it has been considered as a new target for therapy in AML. The study of Msi2 protein expression in AML cases has not been performed in Malaysia, to date. The main aim of the present study was to observe the expression of Msi2 protein in AML patients by immunohistochemistry (IHC) and to correlate its expression with the well-established prognostic and clinical parameters in AML as well as the overall survival (OS). Sixty four bone marrow trephine biopsy sections were immunostained for Msi2 protein. The percentage of blasts with positive reaction and the intensity of the cytoplasmic and nuclear staining were evaluated. The expression of Msi2 protein was found in 95.3% cases with Msi2 pattern varying between the cases. In 71.9% of cases, the blasts showed total cellular positivity and 23.4% cases showed only cytoplasmic positivity. Majority showed high expression of Msi2 for cytoplasmic staining. Interestingly, there was significant correlation between total cellular staining and the intermediate cytogenetic subgroup (P= 0.04). In conclusion, the results showed that the majority of the patients had high expression of Msi2 but this did not correlate to OS. However, the Msi2 expression correlated to the cytogenetic findings. The results suggest future extensive research to be conducted in order to ascertain the exact role of Msi2 positive blast cells in AML in our population and their association with prognosis and outcome.
Keywords :
AML,
cytogenetics,
Immunohistochemistry,
Msi2 protein,
Correspondance Address
Omayma Saad Eldeen Bakheet, Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. Tel: 603-91455373 Fax: 603-91456676 E-mail: ombakheet@gmail.com
References
Back, M., Byers, R. 2013. Co-expression of Musashi 2 and HOXA9 in Acute Myeloid Leukaemia. PhD thesis. The University of Manchester. Barbouti, A., Höglund, M., Johansson, B., Lassen, C., Nilsson, P.G., Hagemeijer, A., Mitelman, F., Fioretos, T. 2003. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23). Cancer Res 63(6): 1202-6. Byers, R.J., Currie, T., Tholouli, E., Rodig, S.J., Kutok, J.L. 2011. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. Blood 118(10): 2857-67. Estey, E., Döhner, H. 2006. Acute myeloid leukaemia. Lancet 368(9550): 1894-1907. Foran, J.M. 2010. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol 2010: 47-55. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J., Burnett, A.K. 2010. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3): 354-65. Hämäläinen, S., Kuittinen, T., Matinlauri, I., Nousiainen, T., Koivula, I., Jantunen, E. 2009. Severe Sepsis in Neutropenic Haematological Patients. PhD thesis. University of Kuopio, Department of Medicine. Han, Y., Ye, A., Zhang, Y., Cai, Z., Wang, W., Sun, L., Jiang, S., Wu, J., Yu, K., Zhang, S. 2015. Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin. PLoS One 10(8): e0136484. Hoffbrand, A.V., Catovsky, D., Tuddenham, G.D.E., Green, A.R. 2011. Postgraduate Haematology. UK, John Wiley & Sons Ltd; 468. Hope, K.J., Cellot, S.,Ting, S.B., MacRae, T., Mayotte, N., Iscove, N.N., Sauvageau, G. 2010. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Cell Stem Cell 7(1): 101-13. Kawahara, H., Imai, T., Imataka, H., Tsujimoto, M., Matsumoto, K., Okano, H. 2008. Neural RNA-binding protein Musashi1 inhibits translation initiation by competing with eIF4G for PABP. J Cell Biol 181(4): 639-53. Kharas, M.G., Lengner, C.J., Al-Shahrour, F., Bullinger, L., Ball, B., Zaidi, S., Morgan, K., Tam, W., Paktinat, M., Okabe, R., Gozo, M., Einhorn, W., Lane, S.W., Scholl, C., Fröhling, S., Fleming, M., Ebert, B.L., Gilliland, D.G., Jaenisch, R., Daley, G.Q. 2010. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 16(8): 903-8. Kumar, C.C. 2011. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2(2): 95-107. Meng, C.Y., Noor, P.J., Ismail, A., Ahid M.F., Zakaria, Z. 2013. Cytogenetic Profile of de novo Acute Myeloid Leukemia Patients in Malaysia. Int J Biomed Sci 9(1): 26-32. Munker, R. 2007. Acute Myelogenous Leukemias. In Modern Hematology: Biology and Clinical Management. 2nd edition. Edited by Munker, R., Hiller. E., Glass, J., Paquette, R. Totowa: Humana Press Inc; 155-72. Park, S.M., Gönen, M., Vu, L., Minuesa, G., Tivnan, P., Barlowe, T.S., Taggart, J., Lu, Y., Deering, R.P., Hacohen, N., Figueroa, M.E., Paietta, E., Fernandez, H.F., Tallman, M.S., Melnick, A., Levine, R., Leslie, C., Lengner, C.J., Kharas, M.G. 2015. Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program. J Clin Invest 125(3): 1268-98. Sakakibara, S., Nakamura, Y., Yoshida, T., Shibata, S., Koike, M., Takano, H., Ueda, S., Uchiyama, Y., Noda, T., Okano, H. 2002. RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation. Proc Natl Acad Sci U S A 99(23): 15194-9. Stone, R.M., O’Donnell, M.R., Sekeres, M.A. 2004. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004: 98-117. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Vardiman, J.W. 2008. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 118.
